Abstract
Purpose: :
PURPOSE.Vascular endotelial growth factor is essential for neovascularization.The use of anti VEGF therapies has largely shown to inhibit this process.Here, the penetration of topical bevacizumab in anterior chamber and its effects on VEGF levels in humor acqueous
Methods: :
METHODS.VEGF humour levels were measured after application of bevacizumab topical eye drops, four times a day in 20 patients who were going to undergo to chataract surgery.The study was based on standard sandwich enzyme-linked immuno sorbent assay technology and an undirect method. Each Humour sample and specific detection polyclonal antibody were added to the wells and then washed away with PBS buffer.an enzymatic complex was used to visualize enzymatic reaction.The catalyzed product produce a blue color that changed in yellow after adding acidic stop solution.the density of yellow is proportional to the human VEGF amount of sample captured in plate.The results were compared with case control
Results: :
RESULTS.The application of bevacizumab topical eye drops determine acqueous VEGF levels reduction compared with case control with a standard deviation of 0,036 and a medium value of 0,140, respectly instead of 0,039 and 0,036.No negative effects were reported.
Conclusions: :
CONCLUSION.Topical application of Bevacizumab, can penetrate anterior chamber and can inhibit VEGF cytokines by reducing their levels.We need to examine many more patients but,in future, Avastin eye drops would mean the same anti VEGF effects with less complicance than intravitreal use.
Keywords: drug toxicity/drug effects • vascular endothelial growth factor • anterior chamber